drugset / Trial / NCT00376285

Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

NCT00376285

Phase 1 Withdrawn Pfizer
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Timeline

Start
2006-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject DIRLOTAPIDE Small molecule
Subject Fenofibrate Small molecule

Indications